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LESIONS AT THE JUNCTION BETWEEN UNCALCIFIED AND CALCIFIED
CARTILAGE ZONES DURING THE DEVELOPMENT OF OSTEOARTHRITIS
Z. Zhang y, J. Molligan z, J. Beckett x, L. Schon z. yMedstar Hlth. Res. Inst.,
Baltimore, MD, USA; zUnion Mem. Hosp., Baltimore, MD, USA; x Saint
Louis Univ., St. Louis, MO, USA
Purpose: Characterization of lesions developed at the junction between
the uncalciﬁed and calciﬁed cartilage zones in the joints with excessive
running-induced osteoarthritis (OA).
Methods: An excessive running protocol (55 km in 6 weeks) was used
to induce osteoarthritis in the knees of Wistar rats (20 weeks old by the
end of the study). Knee joints of the running (n¼6) and control (n¼6)
rats were dissected for histology. Tissue sections were stained with
Safranin O and graded for the severity of OA in the running rats. In the
knees of running rats, OA was conﬁrmed by cartilage surface irregu-
larity, depletion of aggrecan from the matrix and signiﬁcantly increased
Mankin's score. On tissue sections, the incidences of a “cyst-like” lesion
at the junction between uncalciﬁed and calciﬁed cartilage zones in both
osteoarthritic and control knees were calculated. Immunohistochem-
istry of types II and VI collagen, MMPs 9 and 13, VEGFR was performed
to characterize the lesion.
Results: At least one cyst-like lesion was found in 5/6 OA knees in the
running rats, but only 2/6 in the control rats. SomeOA joints hadmultiple
cysts at the junctionbetweenuncalciﬁedandcalciﬁed cartilage zones. The
lesions in different joints varied greatly in size, shape and distance to the
cartilage surface. They rarely penetrated through the tidemark and this
made most of the cysts ﬂat facing the tidemark (Fig, Safranin O staining).
Cysts appeared expanding into the uncalciﬁed cartilage and a few had
openings at the cartilage surface. Most of the cysts were void, but some
with matrix residuals. No chondrocytes were found inside of the cysts.
The cysts were either located in or neighbored with the areas of pre-
oteoglycan depletion. Themargin of the cysts was high intensity of type II
collagen. There was type VI collagen staining in the cyst content, but not
on the margin. Not the matrix immediately surrounding the cysts, but in
the neighboring areas were MMP13 positive. Chondrocytes around the
cysts were not stained with VEGFR and MMP9.
Conclusion: This study described and characterized a cyst-like lesion at
the junction between the uncalciﬁed and calciﬁed cartilage zone in
excessive running induced osteoarthritic knees. The transition from
uncalciﬁed cartilage to calciﬁed cartilage at the tidemark represents
a major alteration of the biological and mechanical properties of artic-
ular cartilage. The cyst-like lesion at the junction between uncalciﬁed
and calciﬁed cartilage zone has not been directly linked to the
pathology of OA. Its location, however, suggests it could play an
important role during the development of OA.
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CROSS-SECTIONAL AND LONGITUDINAL ASSOCIATIONS BETWEEN
SYSTEMIC AND SUBCHONDRAL BONE MINERAL DENSITY AND
KNEE CARTILAGE THICKNESS IN OLDER ADULTS WITH OR
WITHOUT RADIOGRAPHIC OSTEOARTHRITISC. Ding y,z, Y. Cao y, O. Stannus y, D. Dore y, B. Antony y, G. Jones y. yUniv. of
Tasmania, Hobart, Australia; zMonash Univ., Melbourne, Australia
Purpose: To investigate cross-sectional and longitudinal associations
between systemic bone mineral density (BMD), subchondral BMD
(sBMD) and knee cartilage thickness in older adults with or without
radiographic osteoarthritis (ROA).
Methods: A prospective cohort of 158 randomly selected subjects
(mean 63 years, 48% female) including 69 non-ROA and 89 ROA subjects
were studied at baseline and 2.7 years later. Knee cartilage thickness at
medial tibial, lateral tibial, femoral and patellar sites was semi-auto-
matically determined from T1-weighted fat suppressed magnetic
resonance imaging (MRI). Total body, total hip, spine BMD and medial
and lateral tibial sBMD were measured by dual energy x-ray absorpti-
ometry (DXA).
Results: Cross-sectionally, total body, total hip, spine BMD and/or
lateral sBMD were signiﬁcantly and positively associated with
femoral, lateral tibial and/or patellar cartilage thickness in subjects
with ROA after adjustment for potential confounders. Longitudinally,
total body BMD was associated with increased femoral cartilage
thickness (b: 0.33 mm per g/cm2, 95% CI: 0.13, 0.54), spine BMD was
associated with increased femoral and lateral tibial cartilage thick-
ness (b: 0.26 mm per g/cm2, 95% CI: 0.10, 0.42; and b: 0.18 mm per g/
cm2, 95% CI: 0.02, 0.35, respectively), and medial sBMD was associ-
ated with increased medial tibial cartilage thickness (b: 0.44 mm per
g/cm2, 95% CI: 0.01, 0.86) in subjects with ROA. There were no
signiﬁcant associations between BMD and cartilage thickness in
subjects without ROA.
Conclusions: Both systemic and subchondral BMD are associated with
increased cartilage thickness in subjects with ROA, suggesting BMDmay
play a protective role against cartilage loss in knee OA.
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ASSOCIATIONS BETWEEN MEASURES OF OBESITY OVER 10 YEARS
AND PATELLA CARTILAGE IN A POPULATION-BASED COHORT OF
YOUNG TO MIDDLE AGED, ASYMPTOMATIC WOMEN
A.J. Gunardi y, S.L. Brennan z,x, Y. Wang y, F.M. Cicuttini y, J.A.
Pasco z,x, M.A. Kotowicz z,x, G.C. Nicholson k, A.E. Wluka y. yMonash
Univ., Melbourne, Australia; zUniv. of Melbourne, Melbourne, Australia;
xDeakin Univ., Geelong, Australia; kUniv. of Queensland, Queensland,
Australia
Purpose: Osteoarthritis most commonly affects the patellofemoral
compartment of the knee, being a major cause of pain and disability.
The structural changes that evolve prior to the onset of symptoms can
be visualised using magnetic resonance imaging (MRI). There is little
known about the role of obesity on the early structural changes in the
patella cartilage in younger, asymptomatic adult females.
Methods: 160 asymptomatic women (20-49years) participating in the
Geelong Osteoporosis Study underwent knee MRI between 2006-8.
Weight and body mass index (BMI) were measured 10 years prior
(1994-7, baseline) and at the time of the MRI (current) with change over
the period calculated (current-baseline). The relationships between the
measures of obesity and patella cartilage volume and defects were
examined.
Results: After adjustment for age and patella bone volume, there was
a reduction of 13 (95% CI -25.7, -0.55) microliters (mL) in patella carti-
lage volume for every 1 unit increase in current BMI and reduction of
27mL (95% CI -52.6, -1.5) per BMI unit increase over 10 years (p¼0.04 for
both). There was no signiﬁcant association between baseline BMI and
patella cartilage volume (p¼0.16). Increased baseline and current
weight and BMI were associated with increased prevalence of patella
cartilage defects (all p<0.001).
Conclusions: Obesity and weight gain over midlife are both associated
with detrimental structural change at the patella in young to middle
aged healthy women without clinical osteoarthritis. Maintaining
a healthy weight, avoiding obesity and weight gain in younger
asymptomatic women may be important in the prevention of patello-
femoral osteoarthritis.
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USE OF LOW DOSE ASPIRIN IS ASSOCIATED WITH REDUCED MEDIAL
TIBIAL CARTILAGE LOSS IN SYMPTOMATIC OSTEOARTHRITIS: DATA
FROM A COHORT STUDY
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S244A.E. Wluka y, C. Ding z, Y. Wang y, G. Jones z, F.M. Cicuttini y. yMonash
Univ., Melbourne, Australia; zUniv. of Tasmania, Hobart, Australia
Purpose: Inﬂammation and vascular disease have recently been shown
to play a role in the pathogenesis of osteoarthritis (OA). Low dose
aspirin is commonly used in the prevention of cardiovascular disease.
Its effects have been attributed to a variety of actions, including anti-
inﬂammatory effects and effects on platelet function (both anti-
thrombotic and anti-inﬂammatory) and lipids. However whether it
affects human joints has not been studied. The aim of this study was to
examine whether the use of low dose aspirin affects change in knee
cartilage volume over 2 years.
Methods: 117 people with symptomatic knee OA underwent magnetic
resonance imaging of the knee at baseline and 2 years later. Medial and
lateral tibial cartilage volumes weremeasured using validatedmethods.
Annual absolute change and annual percentage change in cartilage
volumewere calculated. Information about regular low dose aspirin use
was collected at baseline, 6, 12 and 24 months. Participants who re-
ported taking regular low dose aspirin (<¼ 150 mg per day) at more
than 1 time point were deﬁned as being aspirin users.
Results: Twenty six participants reported taking aspirin at more than
one visit, with 91 not taking aspirin. At baseline, the only signiﬁcant
difference between the 2 groups was that those taking aspirin were
older than those who did not (p ¼ 0.03).
In those taking aspirin, annual change in medial tibial cartilage volume
and annual percentage change in cartilage volume was approximately
half that seen in those not taking aspirin (-50 vs. -102mm3 and -2.5% vs.
-5.5%, respectively, P¼0.04 for both). These differences became more
signiﬁcant after adjusting for age, gender, body mass index, initial
cartilage volume and severity of radiographic change in the medial
compartment. The annual change in medial tibial cartilage volume was
-40 mm3 (95% conﬁdence interval (CI) -83, 1.3) in aspirin users vs. -105
mm3 (95% CI -127, -82) in non-aspirin users (P ¼ 0.009 for difference).
The annual percentage change in medial tibial cartilage volume was
-2.0% (95% CI -4.6, 0.53) in aspirin users vs. -5.6% (95% CI -6.9, -4.0) in
non-aspirin users (P¼0.02 for difference). There were no signiﬁcant
differences observed in change in lateral tibial cartilage volume.
Conclusion: This study showed that in people with knee OA, the use of
low dose aspirinwas associatedwith reducedmedial tibial cartilage loss
over 2 years. This requires conﬁrmation in a randomised controlled
trial. If this hypothesis were proven, aspirin may provide a cost effective
disease modifying therapy for OA as it is a cheap medication that is
already in common use and known to be well tolerated.462
INTERACTIONS BETWEEN S100A8 AND DDR2 MECHANISMS IN
CARTILAGE DEGRADATION IN OSTEOARTHRITIS
A. van Hummel y,z, L. Xu x, C. Little z, T. Vogl k, J. Roth k, H. Zreiqat y, Y.
Li x. y Tissue Engineering and Biomaterials Unit, Faculty of Engineering,
The Univ. of Sydney, Sydney, Australia; zRaymond Purves Bone and Joint
Res. Lab., The Kolling Inst. of Med. Res., Univ. of Sydney, Royal North
Shore Hosp., Sydney, Australia; xDept. of Dev.al Biology, Harvard Sch. of
Dental Med., Boston, MA, USA; k Inst. of Immunology, Univ. of Muenster,
Muenster, Germany
Purpose: The surface bound tyrosine kinase receptor Ddr2 has been
reported to play a role in early osteoarthritis (OA) pathogenesis.
Increased levels of HtrA1 and degradation of the chondrocyte peri-
cellular matrix expose collagen II ﬁbrils, which activate Ddr2 upon
binding, and lead to increased expression and activation of MMP-13.
Pathology is delayed in surgically induced OA in Ddr2+/-mice, and Ddr2,
HtrA1 and MMP-13 are all increased in a spontaneous model of OA in
Col11a1+/- mice from 6 months of age. S100A8 and S100A9 have also
been implicated in the induction of chondrocyte MMP-13, and are well
known to be up-regulated at both the mRNA and protein level in
inﬂammatory mouse models of arthritis. In contrast to inﬂammatory
models, in a surgically-induced post-traumatic OA, chondrocyte S100A8
and S100A9 mRNA are up-regulated but they are not detected in
cartilage at the protein level. The aim of this study was to determine if
there is a link between the Ddr2 pathway and S100A8 and/or S100A9 in
the pathogenesis of OA cartilage pathology by examining S100A8 and
A9 expression in the Coll11a1+/- model where Ddr2 and HtrA1 are
present, and by determining the effect of S100A8 and S100A9 on Ddr2
and HtrA1 expression in mouse cartilage.Methods: S100A8 and S100A9 expression was examined in the knee
cartilage of Col11a1+/- mice and wild-type (WT) littermates at 3 and 9
months of age using immunohistochemistry (n¼ 3 of both genotypes at
both times; archival sections from mice with antigen-induced arthritis
(AIA) used as a positive control).
Mouse femoral head cartilage explants were dissected from 15WTmice
between the ages of 6-8 weeks old, homogenised, and the explanted
cartilage distributed evenly amongst wells, and cultured in serum-free
media  0.1mM murine S100A8 or S100A9 for 24 hours (n¼2 wells/
treatment). Gene expression of Ddr2, HtrA1 was determined by quan-
titative RT-PCR and normalised to Gapdh expression.
Results: S100A9 protein was not detected in the cartilage of 3 or 9
month old mice of either genotype although strong positive staining
was observed in bone marrow of all mice, as well as cartilage from AIA
animals. In addition to marrow and AIA cartilage samples, S100A8
protein was weakly detected in some chondrocytes/pericellular matrix
in non-calciﬁed cartilage in 1 of the 3 WT and Coll11a1+/- mice at 3
months of age. In contrast S100A8 was localized to chondrocytes/per-
icellular matrix of non-calciﬁed cartilage and meniscal cells in all 9
month old animals, with no difference observed between genotypes. In
mouse femoral cartilage explant cultures, gene expression of Ddr2 was
increased by S100A8, but decreased by S100A9, while HtrA1 was
decreased by both S100A8 and S100A9.
Conclusions: Whilst S100A8 staining was observed in non-calciﬁed
cartilage of some 3 month old and all 9 month old mice, there was no
differential regulation between genotypes, suggesting that whilst an
increase in S100A8 in cartilage may be an age-related change, it is not
associated with the accelerated cartilage degradation seen in the
Col11a1+/- model. In contrast, no S100A9 staining was observed in the
cartilage of any mice from either genotype or age, and therefore may
not be associated either with OA- or age-related cartilage changes. Gene
expression data from femoral head cartilage cultures, however, suggests
that S100A8 but not S100A9 can increase Ddr2 mRNA, providing a link
between these degradative cartilage pathways. However the down-
regulation of HtrA1 mRNA by the S100 proteins suggests that an alter-
native mechanism for exposure of the Ddr2 ligand would be required.
Taken together, this data suggests that whilst S100A8 is not associated
with cartilage degradation in Col11a1+/-, it may pre-dispose the cartilage
to degradation via up-regulation of Ddr2.
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PPARDELTA AS A NOVEL TARGET FOR OSTEOARTHRITIS THERAPY
A. Ratneswaran, E. LeBlanc, S. Ohora, M. Pest, F. Beier. Western Univ.,
London, ON, Canada
Introduction: Osteoarthritis (OA) is a degenerative disorder associated
with the breakdown of articular cartilage. The mechanisms responsible
for this condition are not well understood and therefore no treatments
exist to halt or delay the progression of OA. Recent ﬁndings from our
laboratory indicate that activation of the transcription factor PPARdelta
induces the expression of enzymes involved in proteoglycan breakdown
and can lead to cartilage degeneration in OA, prompting us to speculate
whether inhibition of PPARdelta, can protect from cartilage breakdown
in OA.
Purpose: To evaluate the role of PPARdelta in Osteoarthritis through all
encompassing in-vitro, ex-vivo and in-vivo models of disease.
Methods: To test this, human chondrocytes and mouse femoral head
cartilage explants were treated with pharmacological agonist
(GW501516) and antagonists of PPARdelta (GSK3787/0660) to evaluate
changes in gene expression (qPCR), and histology (Safranin-O, immu-
nohistochemistry) consistent with OA, and to determine if recoverywas
possible.
Our in-vivo approach uses the Cre-Lox system to inactivate PPARdelta
speciﬁcally in the cartilage of using a surgical model of OA. Mutant and
control mice aged 20 weeks are being compared 8 weeks after
a destabilization of medial meniscus (DMM) surgery, based on the
principle that changes in biomechanical load drive cartilage degener-
ation. In order to assess the progression of OA between groups, histo-
pathological scoring (OARSI) and immunohistochemistry for known
markers of OA, (MMP 13, cartilage matrix breakdown products) are
being analyzed. Serum analyses for extracellular matrix markers of
cartilage breakdown are being conducted. To investigate changes in
joint loading during OA, mutant and control mice are being compared
through gait analyses using the CatWalk system that measures load on
